George Kottayil - Acasti Pharma Chief US
| ACSTDelisted Stock | USD 3.37 0.01 0.30% |
Insider
George Kottayil is Chief US of Acasti Pharma
| Age | 61 |
| Phone | 818-839-4378 |
| Web | https://www.acastipharma.com |
George Kottayil Latest Insider Activity
Tracking and analyzing the buying and selling activities of George Kottayil against Acasti Pharma stock is an integral part of due diligence when investing in Acasti Pharma. George Kottayil insider activity provides valuable insight into whether Acasti Pharma is net buyers or sellers over its current business cycle. Note, Acasti Pharma insiders must abide by specific rules, including filing SEC forms every time they buy or sell Acasti Pharma'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
George Kottayil over a year ago Acasti Pharma exotic insider transaction detected |
Acasti Pharma Management Efficiency
The company has return on total asset (ROA) of (0.1162) % which means that it has lost $0.1162 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1856) %, meaning that it created substantial loss on money invested by shareholders. Acasti Pharma's management efficiency ratios could be used to measure how well Acasti Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Acasti Pharma currently holds 11.56 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Acasti Pharma has a current ratio of 10.91, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Acasti Pharma's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Ian MBA | Jaguar Animal Health | 56 | |
| Robert Lutz | Ibio Inc | 55 | |
| CPA CPA | Tonix Pharmaceuticals Holding | 50 | |
| Mike Jenkins | Ibio Inc | N/A | |
| Thomas Walker | Bio Path Holdings | N/A | |
| FACP MD | Moleculin Biotech | 70 | |
| FACP MD | Ocugen Inc | N/A | |
| Margaret MD | Pulmatrix | 67 | |
| Amro Albanna | Aditxt Inc | 54 | |
| McKee MD | GeoVax Labs | 72 | |
| Victoria Rac | Bio Path Holdings | N/A | |
| Donald Picker | Moleculin Biotech | 78 | |
| Jacqueline Northcut | Moleculin Biotech | 62 | |
| Thomas III | Ibio Inc | 57 | |
| Tiffany MBA | Ocugen Inc | N/A | |
| MBA MBA | Ocugen Inc | 58 | |
| Howard MD | ABVC Biopharma | 67 | |
| Rowena Albanna | Aditxt Inc | 58 | |
| Peter MBA | Bio Path Holdings | 75 | |
| Mark Newman | GeoVax Labs | 69 | |
| Randy Maddux | Ibio Inc | 63 | |
Management Performance
| Return On Equity | -0.19 | |||
| Return On Asset | -0.12 |
Acasti Pharma Leadership Team
Elected by the shareholders, the Acasti Pharma's board of directors comprises two types of representatives: Acasti Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Acasti. The board's role is to monitor Acasti Pharma's management team and ensure that shareholders' interests are well served. Acasti Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Acasti Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| George Kottayil, Chief US | ||
| Robert CPA, Principal Officer | ||
| Prashant Kohli, Chief Officer | ||
| Amresh Kumar, VP Management | ||
| Janelle DAlvise, President CEO | ||
| Yves Lachance, VP Compliance | ||
| Carrie DAndrea, VP Operations | ||
| Pierre MD, COO CoFounder | ||
| Christine Pelletier, Director HR |
Acasti Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Acasti Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.19 | |||
| Return On Asset | -0.12 | |||
| Current Valuation | 11.17 M | |||
| Shares Outstanding | 10.14 M | |||
| Shares Owned By Insiders | 38.39 % | |||
| Shares Owned By Institutions | 21.22 % | |||
| Number Of Shares Shorted | 154.19 K | |||
| Price To Earning | 15.34 X | |||
| Price To Book | 0.58 X | |||
| Price To Sales | 208.39 X |
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Other Consideration for investing in Acasti Stock
If you are still planning to invest in Acasti Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Acasti Pharma's history and understand the potential risks before investing.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |